AddedRisk Factors
Effective October 3, 2025, Fred Lampropoulos resigned as Chief Executive Officer and President of Merit and Merit’s Board of Directors appointed Martha G. Aronson as a Director and as Merit’s new Chief Executive Officer and President. Additionally, effective January 4, 2026, Mr. Lampropoulos resigned as a Director and Chair of the Board of Merit. While we have endeavored to manage this leadership transition carefully, changes in leadership are inherently difficult and may negatively impact relationships with key customers, suppliers, investors and employees, cause operational or administrative inefficiencies or disruptions, distract from the achievement of our strategic business objectives, harm our workplace culture, result in loss of institutional knowledge, cause additional volatility in our stock price, or other adverse consequences resulting from the anticipated transition, the occurrence of any of which could have a materially adverse effect on our business.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedRisk Factors
We do not maintain key man life insurance on Ms. Aronson. The loss of Ms. Aronson or of certain other key management personnel could have a materially adverse effect on our business, operations and financial condition.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedRisk Factors
Compliance with the FCPA and other anti-bribery laws presents challenges to our operations. Our policies mandate compliance with the FCPA and all other applicable anti-bribery laws. Further, we expect our employees, distributors,
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedRisk Factors
or such other authorities could require a recall of products or allege that our promotional activities misbrand or adulterate our products or violate other legal requirements, which could result in investigations, prosecutions, fines or other civil or criminal actions.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RemovedRisk Factors
U.S. President Donald Trump has expressed a strong desire to impose new or increase existing tariffs on selected goods imported into the United States. Accordingly, on February 1, 2025, President Trump issued three executive orders directing the United States to impose new tariffs on imports from Canada, Mexico and China, and on February 3, 2025, President Trump announced his intention to pause these tariffs on Canada and Mexico for approximately 30 days. A significant
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
government cost-reduction initiatives, including such initiatives implemented by the administration of U.S. President Donald Trump;
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
Successful implementation and execution of our business strategy will require that we effectively manage our growth. As Merit grows, we are often faced with decisions to (i) expand certain product lines and discontinue others, (ii) open or expand new facilities and close others, (iii) allocate resources between new and established markets, or (iv) allocate resources between the expansion of organic business and the acquisition of new product lines. The outcome of each of these decisions is uncertain, and even with the exercise of excellent business judgment, results may not align with expectations. Our management will need to continue to implement changes in certain aspects of our business, improve our information systems, infrastructure and operations to respond to increased demand, attract and retain qualified personnel, and develop, train, and manage an increasing number of employees. We may not have the resources available to implement certain necessary changes, and as a result, growth may be delayed or we may not be able to take advantage of certain business opportunities. Growth has placed, and will likely continue to place, an increasing strain on our management, sales and other personnel, and on our financial, product design, marketing, distribution, technology and other resources. Any failure to manage growth effectively could have a material adverse effect on our business, operations or financial condition.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
distributors exposes us to various risks, including commercial, legal, compliance and reputational risks, the realization of any of which could harm our results of operations and business.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
In October 2020, we entered into a Settlement Agreement with the DOJ to resolve their investigation into our past marketing transactions and practices. Under the Settlement Agreement and related agreements, we paid $18.7 million (which includes interest and certain fees) in exchange for a release from liability for the alleged conduct. The settlement was also conditioned upon our entering into the CIA. Please refer to the discussion in Item 1. “Business - Regulation - Corporate Integrity Agreement.” Our compliance with the CIA has consumed a significant amount of our resources and management’s attention.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
compliance costs and adverse impacts on raw material sourcing, manufacturing operations and the distribution of our products, which could adversely affect our operations and operating results.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RewordedRisk Factors
We used a portion of the proceeds from the sale of the Convertible Notes and borrowed funds under the Amended Fourth A&R Credit Agreement to finance the Recent Acquisitions, but have not identified additional acquisitions or other uses for a significant portion of the proceeds from the sale of the Convertible Notes or borrowed funds under the Amended Fourth A&R Credit Agreement. Acquisitions.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
The availability and price cost of these the raw materials, parts, products components and services required to operate our business are affected by a variety of factors beyond our control, including existing and potential tariffs, tariffs and related counter-measures, changes in supply and demand, general economic conditions, labor and transportation costs, climate change (including existing and prospective laws and regulations), change, competition, import duties, currency exchange rates rates, regulatory changes and political uncertainty around the world.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
During 2024, we experienced significantly elevated commodity and supply chain costs, including the The overall costs of labor, raw materials, energy, packaging materials transportation, construction, services and other inputs energy necessary for the production and distribution of our products. products continue to increase and be volatile.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our ability to accurately forecast demand for our products could be negatively affected by many factors, including product introductions by our competitors, an increase or decrease in customer demand for our products or for products of our competitors, unanticipated changes in general market conditions or regulatory matters and weakening of economic conditions, or decreased consumer confidence.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Further, if If we are unable to maintain (i) competitive and equitable compensation and benefit programs, including incentive programs which reward financial and operational performance, and (ii) an inclusive work culture that aligns our diverse workforce with our mission and values, our ability to recruit, hire, develop, engage, motivate and retain talented and experienced employees could be negatively affected, which could adversely impact our operating business or results and financial condition. of operation.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
There can be no assurance that any product we have recently launched (such as the Wrapsody Device), launched, are preparing for launch, are now developing or that we may seek to develop in the future, will achieve technological feasibility, obtain regulatory approval or reimbursement approval, gain market acceptance. acceptance or command prices consistent with expectations or profitability.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Such increased Increased borrowing limits pursuant to the Amended Fourth A&R Credit Agreement may make it more difficult for us to comply with leverage ratios and other restrictive covenants in the Amended Fourth A&R Credit Agreement. that agreement.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
However, we expect that the VBP tender process in China will continue to have a negative negatively impact on the our revenue we are able to generate in from China in 2025, 2026, and there can be no assurance that the VBP policy will not have a materially adverse effect on our business, operations or financial condition.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our failure to manage these challenges successfully and coordinate the growth of such effectively integrate acquired businesses or other investments could have an adverse impact on our business and our future growth.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Regional conflicts, including the Russian invasion of ongoing conflict in Ukraine, tensions in the Middle East, East and Venezuela, and the risk of increased tensions between China and Taiwan, could limit or prohibit negatively impact our ability to sell our products in or source materials from sanctioned countries.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
The global macroeconomic environment continues to be challenging due to the effects of inflation globally, inflation, instability in global credit markets, uncertainty regarding global central bank monetary policy, policies, instability in the geopolitical environment in many parts of the world, current economic challenges in China, world and other factors.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Periods of diplomatic or armed conflict, such as the ongoing conflict in Ukraine, tensions in the Middle East and in Venezuela and China-Taiwan relations, may result in (i) new and rapidly or evolving sanctions and trade restrictions, which may impair trade with sanctioned individuals and countries, and (ii) negative impacts to regional trade ecosystems among our customers, partners, and us.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
If we are unable to develop and launch new products and enhanced products, our ability to maintain or expand our market position in the markets in which we participate may be materially adversely impacted.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Our operations are subject to various state and federal laws targeting fraud and abuse in the healthcare industry, including the U.S. federal Anti-Kickback Statute, which prohibit any person from knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, to induce or reward either the referral of an individual, or the furnishing or arranging for an item or service, for which payment may be made under federal healthcare programs, such as the Medicare and Medicaid programs.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
The U.S. and many other countries in which we operate have adopted laws and regulations protecting certain data, including medical and personal data (including HIPAA and the HITECH Act), and requiring data holders and controllers to implement administrative, logical and technical controls and procedures in order to protect the privacy of such data.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We have adopted a code of business conduct and ethics, and a global anti-corruption policy, but it is not always possible to identify and deter all misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Further, no No assurances can be given that any patent application we have filed or may file will result in a patent being issued, or that any existing or future patents will afford adequate or meaningful protection against competitors or against similar technologies.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
In May 2025, we completed a merger transaction with Biolife Delaware, L.L.C. (“Biolife”), a manufacturer of unique patented hemostatic devices under the brand names StatSeal® and WoundSeal®. In November 2025, pursuant to the terms of an asset purchase agreement between Merit and Pentax of America, Inc., we acquired the C2 CryoBalloon® device and related technology.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
*Commencing January 1, 2025, we reorganized our sales teams and product categories to include revenues from the sale of our spine devices under our OEM product category. Revenue figures for 2024 and 2023 have been recast to reflect this realignment of our portfolio of spine products, representing approximately $22.6 million and $22.4 million in revenue, respectively, within the OEM product category to provide comparability between the reported periods.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RemovedMD&A
In July 2024, we executed an asset purchase agreement with EndoGastric Solutions, Inc. (“EGS”), acquiring the EsophyX® Z+ device which delivers a durable, minimally invasive non-pharmacological treatment option for patients suffering from GERD. In November 2024, we completed the acquisition of a portfolio of Lead Management products from Cook Medical.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
On December 20, 2024, we announced that the WRAPSODY® Cell-Impermeable Endoprosthesis has received premarket approval from the US Food and Drug Administration (FDA). With this approval, Merit can begin commercialization of the device in the U.S. in 2025.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
Impairment Charges. During the year ended December 31, 2024, we recognized no impairment costs.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
Acquired In-process Research and Development. During the year ended December 31, 2024, we recognized no acquired in-process research and development costs.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RewordedMD&A
The increase in R&D expenses for the year ended December 31, 2024 2025 compared to the year ended December 31, 2023 2024 was primarily related to increased labor-related costs consistent including variable compensation associated with an increase in headcount bonus and an increase materials equity award programs and scrap utilized in R&D, partially offset by lower regulatory costs related to Medical Device Rgulation in the E.U. increased consulting services and clinical trials.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in net income for 2024, 2025, when compared to 2023, 2024, was primarily related to higher sales, sales and higher gross margin as a percentage of sales, decreased contingent consideration expense ($0.4 million in 2024 compared to $1.7 million in 2023), decreased acquired in-process research and development expense ($0 in 2024 compared to $1.6 million in 2023) and decreased other expenses; sales; partially offset by higher SG&A, R&D, other expense and income tax expense.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in the effective income tax rate for 2024 2025 compared to 2023 2024 was primarily the result of decreased benefit from discrete items such as stock-based share-based compensation and foreign contingent liabilities and increased permanent tax credit utilization. differences in various jurisdictions and items related to the budget reconciliation package enacted during the period and retroactive to the beginning of the year.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease increase in other expense for 2024 2025 compared to 2023 2024 was principally the result of an increase a decrease in interest income associated with and increased decreased average cash and cash equivalents and during the period, partially offset by reduced interest expense associated with borrowings under the Amended Fourth A&R Credit Agreement, partially offset by interest expense associated with outstanding convertible debt. Agreement.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Cash paid for income taxes was $45.0 $31.4 million and $31.5 $45.0 million for the years ended December 31, 2024 2025 and 2023, 2024, respectively, primarily due as the result of increased taxes payable and an increased portion of our total tax expense relating to increases in income before tax. deferred tax expense.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Cash outflows invested in acquisitions and other equity investments for the year ended December 31, 2024 2025 were $320.2 $144.8 million and were primarily related to payments required by our merger agreement with Biolife LLC ($120.0 million) and our asset purchase agreements agreement with Cook Medical Holdings LLC ($210.0 million), Endogastric Solutions, Pentax of America, Inc.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Cash paid for income taxes Depreciation and amortization was $45.0 $123.2 million and $31.5 $102.7 million for the years ended December 31, 2024 2025 and 2023, 2024, respectively, primarily due to increases an increase in income before tax. intangible assets as a result of acquisitions.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
This increase in cardiovascular operating income was primarily related to higher increased sales and gross profit, decreased acquired in-process research and development charges, and decreased contingent consideration expense ($0.4 million in 2024 compared to $1.7 million in 2023), partially offset by higher increased SG&A and R&D expenses.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
As of December 31, 2024 2025 and 2023, we had 2024, cash and cash equivalents, including restricted cash, of $18.1 million and $17.6 million, respectively, held by our subsidiary in China. China was $20.0 million and $18.1 million, respectively.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in our international sales during 2024 2025 was primarily a result of higher sales in EMEA, which increased $11.2 $37.9 million or 4.8%, 15.3%, higher ROW Rest of World (“ROW”) sales which increased $8.9 $7.0 million or 18.1%, 12.2%, and higher sales in our Asia Pacific region, which increased $5.3 $5.8 million or 2.1%, 2.3%, compared to the corresponding period of 2023. 2024.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
We base the fair value of identifiable intangible assets acquired in a business combination on valuations that use information and assumptions that a market participant would use, including assumptions for estimated revenue projections, growth rates, cash flows, discount rates, useful life, and other relevant assumptions.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Capital expenditures in each period were primarily related to investment in property and equipment to support development and production of our products. products and in 2025 includes costs for the construction of a new distribution facility in South Jordan, Utah.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new